Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation.

ABSTRACT:

Background

The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). Limited data from the patients' perspective are available on the use of biologics in the treatment of these chronic conditions and this evaluation was designed to collect data from patients who had been prescribed etanercept for the first time. This manuscript describes the self-reported baseline characteristics and health-related quality of life of patients prior to treatment. Follow-up data will be reported separately.

Methods

Patients throughout the United Kingdom prescribed etanercept were invited to participate in an evaluat

SUBMITTER: Wade AG 

PROVIDER: S-EPMC3141801 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature